

In accordance with the requirements of 37 C.F.R. § 1.121, the attached Appendix shows the changes to the specification that have been made by the amendment.

Please enter the attached one page paper copy of the Sequence Listing, filed herewith, into the specification as a separate paper as required by 37 C.F.R. § 1.821(c). Also, please place the diskette containing the computer readable form of the Sequence Listing into the file.

**REMARKS**

The Office has required Applicants to submit a Sequence Listing complying with 37 C.F.R. § § 1.821-1.825. In response, Applicants submit a paper and computer readable form of the Sequence Listing, and a copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures. The undersigned state that the content of the paper copy and the computer readable form of the Sequence Listing are the same. No new matter has been entered.


Applicants have amended the specification to recite the SEQ ID NOs.


Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: April 11, 2001

By:   
Steven P. O'Connor  
Reg. No. 41,225  
(202) 408-4079

By:   
Charles D. Niebylski  
Reg. No. 46,116  
(202) 408-4128

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000

**APPENDIX**  
**CHANGES MADE IN THE AMENDMENT**

Very recently, the applicant has demonstrated that it was also particularly advantageous to use, as adjuvant in transfection compositions, a compound involved, directly or otherwise, in the condensation of nucleic acids. This compound consists, completely or in part, of peptide units (KTPKKAKKP) (SEQ ID NO: 1) and/or (ATPAKKAA) (SEQ ID NO: 2), it being possible for the number of units to vary between 2 and 10. Such an agent can also be derived from a portion of a histone, a nucleolin, a protamine and/or one of their derivatives (WO 96/25508). Such a compound may be advantageously incorporated into the claimed composition.

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000